Largest biotech by earnings
Net income for the latest fiscal year: what was left for shareholders after every cost, interest and tax. A negative figure is a loss.
Gilead Sciences leads the 24 biotech ranked by earnings, at AED 31.3B, ahead of Amgen (AED 28.3B) and Biogen (AED 4.7B). Figures as of 18 Nov 2026, 15:06 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Gilead SciencesAED 31.3B
- Median
- -AED 251.9M
- Combined market value
- AED 3.12T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Earnings ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | AED 31.3B | AED 773.5B | AED 623.62 | 0.28% down | 33% up | ||
| 2 | AmgenAMGN · Health Care | AED 28.3B | AED 898.9B | AED 1,661.91 | 1.19% down | 34% up | ||
| 3 | BiogenBIIB · Health Care | AED 4.7B | AED 136.3B | AED 921.90 | 0.08% up | 49% up | ||
| 4 | argenxARGX · Health Care | AED 4.7B | AED 222.4B | AED 3,537.11 | 1.64% up | 4% up | ||
| 5 | ExelixisEXEL · Health Care | AED 2.9B | AED 62B | AED 254.20 | 1.04% up | 63% up | ||
| 6 | Neurocrine BiosciencesNBIX · Health Care | AED 1.8B | AED 61B | AED 602.39 | 1.15% down | 20% up | ||
| 7 | QiagenQGEN · Health Care | AED 1.6B | AED 37.7B | AED 182.56 | 0.09% down | 12% up | ||
| 8 | Halozyme TherapeuticsHALO · Health Care | AED 1.2B | AED 40.7B | AED 356.90 | 1.25% up | 37% up | ||
| 9 | Krystal BiotechKRYS · Health Care | AED 752.3M | AED 33.6B | AED 1,135.22 | 3.53% up | 46% up | ||
| 10 | Bio-TechneTECH · Health Care | AED 668M | AED 42B | AED 267.13 | 0.14% up | 26% up | ||
| 11 | RepligenRGEN · Health Care | AED 179.6M | AED 40.7B | AED 635.96 | 6.76% up | 5% up | ||
| 12 | Adaptive BiotechnologiesADPT · Health Care | -AED 218.5M | AED 17.3B | AED 106.62 | 1.90% up | 88% up | ||
| 13 | Twist BioscienceTWST · Health Care | -AED 285.3M | AED 29.6B | AED 434.47 | 5.62% up | 340% up | ||
| 14 | CG OncologyCGON · Health Care | -AED 591.3M | AED 25.4B | AED 284.45 | 1.89% down | 85% up | ||
| 15 | Kodiak SciencesKOD · Health Care | -AED 844.6M | AED 23.8B | AED 363.62 | 2.27% up | 396% up | ||
| 16 | Kymera TherapeuticsKYMR · Health Care | -AED 1.1B | AED 38.8B | AED 454.14 | 1.75% up | 87% up | ||
| 17 | ImmunityBioIBRX · Health Care | -AED 1.3B | AED 25.5B | AED 24.00 | 4.39% up | 193% up | ||
| 18 | Scholar Rock HoldingSRRK · Health Care | -AED 1.4B | AED 21.4B | AED 175.38 | 5.92% up | 14% up | ||
| 19 | ImmunovantIMVT · Health Care | -AED 1.9B | AED 25.6B | AED 123.92 | 1.60% up | 43% up | ||
| 20 | CRISPR TherapeuticsCRSP · Health Care | -AED 2.1B | AED 15B | AED 154.70 | 4.91% up | 21% down | ||
| 21 | VaxcytePCVX · Health Care | -AED 2.8B | AED 34.5B | AED 217.80 | 0.17% down | 22% up | ||
| 22 | Revolution MedicinesRVMD · Health Care | -AED 4.2B | AED 128.7B | AED 595.16 | 0.40% down | 131% up | ||
| 23 | BioNTechBNTX · Health Care | -AED 4.6B | AED 77.4B | AED 312.09 | 0.13% up | 16% down | ||
| 24 | ModernaMRNA · Health Care | -AED 10.4B | AED 308.5B | AED 762.37 | 0.37% up | 755% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Earnings is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6729 AED).
Questions and answers
Which biotech rank first by earnings?
Gilead Sciences (AED 31.3B), Amgen (AED 28.3B) and Biogen (AED 4.7B) are the top three of the 24 biotech ranked by earnings as of 18 Nov 2026, 15:06 UTC.
How many biotech are in this ranking?
24 are ranked by earnings.
What are these biotech worth together?
The 24 biotech ranked by earnings have a combined market value of AED 3.12T as of 18 Nov 2026, 15:06 UTC.
What does ranking by earnings measure?
Net income for the latest fiscal year: what was left for shareholders after every cost, interest and tax. A negative figure is a loss.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest biotech by earnings”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=earnings
Underlying data: Yahoo Finance; SEC EDGAR.